Zavegepant

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 462368

CAS#: 1337918-83-8 (free base)

Description: Zavegepant, also known as Vazegepant, BHV-3500 and BMS 742413, is a highly potent, selective and structurally unique small molecule CGRP receptor antagonist. Vazegepant is the first and only CGRP receptor antagonist for intranasal administration currently in development for the acute treatment of migraine.


Chemical Structure

img
Zavegepant
CAS# 1337918-83-8 (free base)

Theoretical Analysis

MedKoo Cat#: 462368
Name: Zavegepant
CAS#: 1337918-83-8 (free base)
Chemical Formula: C36H46N8O3
Exact Mass: 638.37
Molecular Weight: 638.817
Elemental Analysis: C, 67.69; H, 7.26; N, 17.54; O, 7.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1414976-20-7 (HCl)   1337918-83-8 (free base)  

Synonym: Zavegepant, Vazegepant; BMS 742413; BMS-742413; BMS742413; BHV-3500; BHV 3500; BHV3500;

IUPAC/Chemical Name: (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide

InChi Key: JJVAPHYEOZSKJZ-JGCGQSQUSA-N

InChi Code: InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1

SMILES Code: CN1CCC(N2CCN(C([C@H](NC(N3CCC(C4=CC(C=CC=C5)=C5NC4=O)CC3)=O)CC6=CC(C=NN7)=C7C(C)=C6)=O)CC2)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 638.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. J Med Chem. 2020;63(13):6600-6623. doi:10.1021/acs.jmedchem.9b01810

2: Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Curr Opin Neurol. 2020;33(3):309-315. doi:10.1097/WCO.0000000000000806.